<DOC>
	<DOCNO>NCT00716573</DOCNO>
	<brief_summary>After transplantation , renal impairment , incidence progression atherosclerosis lead modification immunosuppressive regimen , switch , reduction discontinuation CNI and/or introduction everolimus . The risk benefit strategy clearly evaluate specific clinical trial . This study specifically design evaluate impact everolimus introduction , calcineurin dose reduction , less one year cardiac transplantation , renal clinical outcome , specially : - Renal function improvement - Vasculopathy major cardiac event reduction - Maintenance immunosuppressive efficacy</brief_summary>
	<brief_title>Efficacy Study Everolimus Renal Function Heart Transplant Recipients With Established Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female cardiac recipient 18 year old First second heart transplant , one year follow surgery Patients renal failure assess cGFR 30 60 ml/min/1,73m² calculate MDRD4 formula Patients volunteer participate study , write informed consent sign Affiliation national health insurance program Current CNIfree immunosuppressive regimen Patients currently previously treat mTOR inhibitor time prior randomization Patients recipients multiple solid organ transplant Treated acute rejection episode within three month prior randomization Congestive heart failure ( NYHA class III IV ) and/or VEF &lt; 30 % and/or patient wait retransplantation Scheduled surgical intervention Platelet count &lt; 50 G/l Severe hepatic insufficiency ( SGPT and/or SGOT &gt; 3N ) Major lipidic profile abnormality ( total cholesterol &gt; 3g/l and/or TG &gt; 5g/l ) Proteinuria/creatinuria &gt; 0,08 g/mmol Severe renal failure attest cGFR &lt; 30 ml/min/1.73m² ( MDRD4 ) History Hypersensitivity everolimus , sirolimus excipients History Hypersensitivity macrolides Pregnancy breast feed Childbearing age woman without efficient contraception Law protect patient Patients emergency unable express consent History Hypersensitivity cyclosporine StJohn 's wort , stiripentol , bosentan , rosuvastatin History Hypersensitivity tacrolimus , macrolides excipients History Hypersensitivity azathioprine History Hypersensitivity mycophénolate mofetil excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Cardiac transplantation</keyword>
	<keyword>Chronic renal insufficiency</keyword>
	<keyword>Everolimus</keyword>
</DOC>